NCT06795412 2026-03-06
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Pyxis Oncology, Inc
Phase 1/2 Recruiting
Pyxis Oncology, Inc
RemeGen Co., Ltd.
LaNova Medicines Limited
RemeGen Co., Ltd.
Exscientia AI Limited
Heidelberg Pharma AG